T. Lawniczek

发表

A 1-year randomized controlled trial of deferasirox vs deferoxamine for myocardial iron removal in β-thalassemia major (CORDELIA).

D. Pennell, A. Piga, Yiyun Zhang, 2014, Blood.

Baseline Characteristics and Symptom Burden in RESPONSE: A Randomized, Open-Label, Phase 3 Study of Ruxolitinib In Polycythemia Vera Patients Resistant to or Intolerant of Hydroxyurea

M. Griesshammer, S. Verstovsek, C. Harrison, 2013 .

A Multicenter, Randomized, Open-Label Trial Evaluating Deferasirox Compared with Deferoxamine for the Removal of Cardiac Iron in Patients with β-Thalassemia Major and Iron Overload (CORDELIA).

D. Pennell, A. Piga, Yiyun Zhang, 2012 .

In-vitro Immunomodulatory Effects of Haloperidol and Perazine in Schizophrenia

A. Madej, D. Belowski, Z. Herman, 2000, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Deferasirox (Exjade®) in Patients with Low/Intermediate-1 Risk MDS and Transfusional Iron Overload.

G. Garcia-Manero, E. Angelucci, D. Bowen, 2009 .

Deferasirox effectively reduces iron overload in non-transfusion-dependent thalassemia (NTDT) patients: 1-year extension results from the THALASSA study

M. Cappellini, V. Viprakasit, R. Galanello, 2013, Annals of Hematology.

Deferasirox reduces iron overload significantly in nontransfusion-dependent thalassemia: 1-year results from a prospective, randomized, double-blind, placebo-controlled study.

Vip Viprakasit, Ali T Taher, Maria Domenica Cappellini, 2012, Blood.

Efficacy and safety of deferasirox doses of >30 mg/kg per d in patients with transfusion-dependent anaemia and iron overload

E. Vichinsky, M. Cappellini, R. Galanello, 2009, British journal of haematology.

Correlation of Bridging and Lymphodepleting Chemotherapy with Clinical Outcomes in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated with Tisagenlecleucel

M. Kersten, G. Salles, U. Jaeger, 2019, Blood.

Deferasirox demonstrates a dose-dependent reduction in liver iron concentration and consistent efficacy across subgroups of non-transfusion-dependent thalassemia patients

Vip Viprakasit, Ali T Taher, Dany Habr, 2013, American journal of hematology.

Deferasirox Continues to Reduce Iron Overload in Non-Transfusion-Dependent Thalassemia: A One-Year, Open-Label Extension to a One-Year, Randomized, Double-Blind, Placebo-Controlled Study (THALASSA)

M. Cappellini, V. Viprakasit, R. Galanello, 2012 .

Reduction in liver iron concentration is consistent across subgroups of non-transfusion-dependent thalassemia patients treated with deferasirox : results from the 1-year thalassa study

V. Viprakasit, R. Galanello, A. Taher, 2012 .

Deferasirox Significantly Reduces Liver Iron Concentration In Non-Transfusion-Dependent Thalassemia Patients with Iron Overload: Results From the 1-Year Randomized, Double-Blind, Placebo-Controlled Phase II THALASSA Study

M. Cappellini, V. Viprakasit, R. Galanello, 2011 .

Randomized Phase II Study Evaluating the Efficacy and Safety of Deferasirox in Non-Transfusion-Dependent Thalassemia Patients with Iron Overload.

M. Cappellini, V. Viprakasit, A. Taher, 2009 .

Safety of deferasirox (Exjade®) in myelodysplastic syndromes (MDS) and non-MDS patients with transfusional iron overload : a pooled analysis focusing on renal function

P. Greenberg, M. Cappellini, M. Schmid, 2009 .

Results of a prospective, randomized, open-label phase 3 study of ruxolitinib (RUX) in polycythemia vera (PV) patients resistant to or intolerant of hydroxyurea (HU): the RESPONSE trial

M. Griesshammer, S. Verstovsek, R. Mesa, 2014 .